ABSTRACT
BACKGROUND: Isoprostanes are bioactive compounds formed by non-enzymatic oxidation of polyunsaturated fatty acids, mostly arachidonic, and markers of free radical generation during inflammation. In aspirin exacerbated respiratory disease (AERD), asthmatic symptoms are precipitated by ingestion of non-steroid anti-inflammatory drugs capable for pharmacologic inhibition of cyclooxygenase-1 isoenzyme. We investigated whether aspirin-provoked bronchoconstriction is accompanied by changes of isoprostanes in exhaled breath condensate (EBC). METHODS: EBC was collected from 28 AERD subjects and 25 aspirin-tolerant asthmatics before and after inhalatory aspirin challenge. Concentrations of 8-iso-PGF2α, 8-iso-PGE2, and prostaglandin E2 were measured using gas chromatography/mass spectrometry. Leukotriene E4 was measured by immunoassay in urine samples collected before and after the challenge. RESULTS: Before the challenge, exhaled 8-iso-PGF2α, 8-iso-PGE2, and PGE2 levels did not differ between the study groups. 8-iso-PGE2 level increased in AERD group only (p=0.014) as a result of the aspirin challenge. Urinary LTE4 was elevated in AERD, both in baseline and post-challenge samples. Post-challenge airways 8-iso-PGE2 correlated positively with urinary LTE4 level (p=0.046), whereas it correlated negatively with the provocative dose of aspirin (p=0.027). CONCLUSION: A significant increase of exhaled 8-iso-PGE2 after inhalatory challenge with aspirin was selective and not present for the other isoprostane measured. This is a novel finding in AERD, suggesting that inhibition of cyclooxygenase may elicit 8-iso-PGE2 production in a specific mechanism, contributing to bronchoconstriction and systemic overproduction of cysteinyl leukotrienes.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Aspirin/analogs & derivatives , Asthma, Aspirin-Induced/metabolism , Cyclooxygenase Inhibitors/toxicity , Dinoprostone/analogs & derivatives , Isoprostanes/agonists , Lung/drug effects , Lysine/analogs & derivatives , Respiratory Mucosa/drug effects , Adult , Aspirin/toxicity , Asthma/metabolism , Asthma/physiopathology , Asthma, Aspirin-Induced/physiopathology , Asthma, Aspirin-Induced/urine , Biomarkers/analysis , Biomarkers/metabolism , Biomarkers/urine , Breath Tests , Bronchial Provocation Tests , Bronchoconstriction/drug effects , Dinoprostone/agonists , Dinoprostone/analysis , Dinoprostone/metabolism , Female , Forced Expiratory Volume/drug effects , Humans , Isoprostanes/analysis , Isoprostanes/metabolism , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/urine , Lung/metabolism , Lung/physiopathology , Lysine/toxicity , Male , Middle Aged , Respiratory Mucosa/metabolism , Respiratory Mucosa/physiopathology , Severity of Illness Index , Single-Blind MethodABSTRACT
The conjunctiva is a mucous membrane that covers the sclera and lines the inside of the eyelids. Throughout the conjunctiva are goblet cells that secrete mucins to protect the eye. Chronic inflammatory diseases such as allergic conjunctivitis and early dry eye lead to increased goblet cell mucin secretion into tears and ocular surface disease. The purpose of this study was to determine the actions of the inflammatory mediators, the leukotrienes and the proresolution resolvins, on secretion from cultured rat and human conjunctival goblet cells. We found that both cysteinyl leukotriene (CysLT) receptors, CysLT(1) and CysLT(2,) were present in rat conjunctiva and in rat and human cultured conjunctival goblet cells. All leukotrienes LTB(4), LTC(4), LTD(4), and LTE(4), as well as PGD(2), stimulated goblet cell secretion in rat goblet cells. LTD(4) and LTE(4) increased the intracellular Ca(2+) concentration ([Ca(2+)](i)), and LTD(4) activated ERK1/2. The CysLT(1) receptor antagonist MK571 significantly decreased LTD(4)-stimulated rat goblet cell secretion and the increase in [Ca(2+)](i). Resolvins D1 (RvD1) and E1 (RvE1) completely reduced LTD(4)-stimulated goblet cell secretion in cultured rat goblet cells. LTD(4)-induced secretion from human goblet cells was blocked by RvD1. RvD1 and RvE1 prevented LTD(4)- and LTE(4)-stimulated increases in [Ca(2+)](i), as well as LTD(4) activation of ERK1/2. We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cell mucous secretion with LTD(4) using the CysLT(1) receptor. Stimulated secretion is terminated by preventing the increase in [Ca(2+)](i) and activation of ERK1/2 by RvD1 and RvE1.
Subject(s)
Conjunctiva/metabolism , Conjunctiva/pathology , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/analogs & derivatives , Goblet Cells/metabolism , Goblet Cells/pathology , Leukotriene D4/physiology , Leukotriene E4/physiology , Aged , Animals , Cells, Cultured , Docosahexaenoic Acids/biosynthesis , Docosahexaenoic Acids/physiology , Eicosapentaenoic Acid/biosynthesis , Eicosapentaenoic Acid/physiology , Eicosapentaenoic Acid/therapeutic use , Female , Humans , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/physiology , Inflammation Mediators/therapeutic use , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/physiology , Leukotriene D4/antagonists & inhibitors , Leukotriene E4/antagonists & inhibitors , Male , Middle Aged , Organ Culture Techniques , Rats , Rats, Sprague-Dawley , Receptors, Leukotriene/metabolismABSTRACT
Leukotrienes are lipid mediators produced via 5-lipooxygenase pathway of arachidonic acid. At least two cysteinyl-leukotrienes receptors are highly expressed in the heart, including the conduction system. Coronary angiography or angioplasty is accompanied by release of cysteinyl leukotrienes into coronary circulation and into urine. We tested the hypothesis that inhibition of leukotrienes biosynthesis would affect the conductance system function. In a double-blind placebo controlled study, patients with stable angina undergoing elective coronary catheterization or angioplasty were randomly assigned to 48 hrs treatment with a 5-lipoxgenase inhibitor (n=54) or placebo (n=49). ECG Holter recording was carried out for 24 hrs before and after the procedure and urinary leukotriene E(4) measurements were done. Inhibition of 5-lipoxygenase caused 26% reduction of urinary leukotriene E(4), associated with: 1) decrease in heart rate by about 7%, 2) enhanced heart rate variability; 3) protection against depressions in atrioventricular conductance and ventricular repolarization induced by the procedure. No effects on either arrhythmias, or ECG patterns of ischemia were noted. We conclude that pharmacological inhibition of 5-lipoxygenase, shortly before percutaneous coronary intervention, reveals specific actions of leukotrienes on the heart rhythm. Inhibitors of 5-lipoxygenase might be of interest as a novel class of cardiac drugs affecting the conductive system.
Subject(s)
Heart Conduction System/drug effects , Heart Rate/drug effects , Heart Rate/physiology , Leukotriene Antagonists/pharmacology , Leukotrienes , Aged , Angina, Unstable/drug therapy , Angina, Unstable/enzymology , Angina, Unstable/urine , Arachidonate 5-Lipoxygenase/biosynthesis , Double-Blind Method , Female , Heart Conduction System/enzymology , Humans , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/biosynthesis , Leukotriene E4/urine , Leukotrienes/biosynthesis , Leukotrienes/metabolism , Leukotrienes/physiology , Lipoxygenase Inhibitors/pharmacology , Male , Middle AgedABSTRACT
The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4), is formed by conjugation of LTA(4) and reduced glutathione by LTC(4) synthase in mast cells, eosinophils, basophils, and macrophages. After extracellular export, LTC(4) is converted to LTD(4) and LTE(4) through sequential enzymatic removal of glutamic acid and then glycine. Only LTE(4) is sufficiently stable to be prominent in biologic fluids, such as urine or bronchoalveolar lavage fluid, of asthmatic individuals and at sites of inflammation in animal models. LTE(4) has received little attention because it binds poorly to the classical type 1 and 2 cysLT receptors and is much less active on normal airways than LTC(4) or LTD(4). However, early studies indicated that LTE(4) caused skin swelling in human subjects as potently as LTC(4) and LTD(4), that airways of asthmatic subjects (particularly those that were aspirin sensitive) were selectively hyperresponsive to LTE(4), and that a potential distinct LTE(4) receptor was present in guinea pig trachea. Recent studies have begun to uncover receptors selective for LTE(4): P2Y(12), an adenosine diphosphate receptor, and CysLT(E)R, which was observed functionally in the skin of mice lacking the type 1 and 2 cysLT receptors. These findings prompt a renewed focus on LTE(4) receptors as therapeutic targets that are not currently addressed by available receptor antagonists.
Subject(s)
Asthma/immunology , Leukotriene E4/metabolism , Receptors, Leukotriene/metabolism , Animals , Asthma/drug therapy , Guinea Pigs , Humans , Leukotriene Antagonists/therapeutic use , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/metabolism , Leukotriene D4/antagonists & inhibitors , Leukotriene D4/metabolism , Leukotriene E4/antagonists & inhibitors , Mice , Receptors, Purinergic P2/metabolism , Skin/immunology , Skin/pathologyABSTRACT
Twenty five years after the structure elucidation of slow reacting substance of anaphylaxis, antileukotrienes are established as a new therapeutic modality in asthma. The chapter reviews the biochemistry and pharmacology of leukotrienes and antileukotrienes with particular focus on the different usage of antileukotrienes for treatment of asthma and rhinitis in Europe and the US. Further research needs and new areas for leukotriene involvement in respiratory diseases are also discussed.
Subject(s)
Asthma/drug therapy , Leukotriene Antagonists/therapeutic use , Lipoxygenase Inhibitors/therapeutic use , Acetates/pharmacology , Acetates/therapeutic use , Animals , Asthma/metabolism , Clinical Trials as Topic , Cyclopropanes , Humans , Hydroxyurea/analogs & derivatives , Hydroxyurea/pharmacology , Hydroxyurea/therapeutic use , Leukotriene Antagonists/pharmacology , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/metabolism , Leukotriene D4/antagonists & inhibitors , Leukotriene D4/metabolism , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/metabolism , Lipoxygenase Inhibitors/pharmacology , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/metabolism , Quinolines/pharmacology , Quinolines/therapeutic use , Receptors, Leukotriene/metabolism , Respiratory System/drug effects , Respiratory System/metabolism , Rhinitis/drug therapy , Rhinitis/metabolism , SulfidesABSTRACT
BACKGROUND: Evidence suggests that small airways contribute to clinically significant processes in asthma. Cysteinyl leukotrienes (CysLTs) are considered to be pivotal mediators in the pathogenesis of asthma. Montelukast (MK), a specific CysLT1 receptor antagonist, is metabolized in two main hydroxylated metabolites (termed M5 and M6, respectively). OBJECTIVES: The aims of this study were to compare the responsiveness of small and large human bronchi to the three CysLTs, to evaluate the antagonist activity of MK, M5 and M6 in these preparations of human bronchi, and to characterize the CysLT receptors involved in the contractile response. METHODS AND RESULTS: In isolated small bronchus (i.d. 0.5-2 mm), the potencies (-log molar EC50) of LTC4, LTD4 and LTE4 were 9.3 (n=11), 9.1 (n=30) and 8.4 (n=14), respectively. The three CysLTs were about 30-fold more potent in small bronchi than in larger bronchi (i.d. 4-6 mm). In small bronchi, MK significantly shifted to the right the CysLT concentration-effect curves with pA2 values against LTC4, LTD4 and LTE4 of 9.1 (n=3), 9.0 (n=11) and 8.7 (n=5), respectively. The antagonist potencies of M6 and M5 were similar to MK and fivefold lower, respectively. A similar activity of MK against the three CysLTs suggested that CysLT1 receptors are involved in the contraction of human bronchus. Analysis by RT-PCR also indicated that human bronchus mainly expressed CysLT1 receptors. CONCLUSION: MK exerts a potent antagonist activity against the particularly potent constricting effects of CysLTs in isolated human small bronchi, which only expressed the CysLT1 receptor subtype. The metabolites of MK are also potent in vitro antagonists, but may not participate in the therapeutic activity of MK due to their low plasma concentrations in patients treated with the recommended dose of MK.
Subject(s)
Acetates/pharmacology , Bronchi/drug effects , Leukotriene Antagonists/pharmacology , Quinolines/pharmacology , Acetates/metabolism , Adult , Aged , Aged, 80 and over , Bronchial Hyperreactivity , Bronchial Provocation Tests , Cyclopropanes , Dose-Response Relationship, Drug , Female , Humans , In Vitro Techniques , Leukotriene Antagonists/metabolism , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/pharmacology , Leukotriene D4/antagonists & inhibitors , Leukotriene D4/pharmacology , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/pharmacology , Male , Middle Aged , Quinolines/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , SulfidesABSTRACT
Previous studies have indicated that increased dietary salt consumption worsens postexercise pulmonary function in humans with exercise-induced asthma (EIA). It has been suggested that EIA and hyperpnea-induced airway obstruction (HIAO) in guinea pigs (an animal model of EIA) are mediated by similar mechanisms. Therefore, the purpose of this study was to determine whether altering dietary salt consumption also exacerbated HIAO in guinea pigs. Furthermore, the potential pathway of action of dietary salt was investigated by blocking leukotriene (LT) production during HIAO in guinea pigs. Thirty-two male Hartley strain guinea pigs were split into two groups. One group (n = 16) of animals ingested a normal-salt diet (NSD) for 2 wk; the other group (n = 16) ingested a high-salt diet (HSD) for 2 wk. Thereafter, animals were anesthetized, cannulated, tracheotomized, and mechanically ventilated during a baseline period and during two dry gas hyperpnea challenges. After the first challenge, the animals were administered either saline or nordihydroguaiaretic acid, a LT inhibitor. Bladder urine was analyzed for electrolyte concentrations and urinary LTE(4). The HSD elicited higher airway inspiratory pressures (Ptr) than the NSD (P < 0.001) postchallenge. However, after infusion of the LT inhibitor and a second hyperpnea challenge, HIAO was blocked in both diet groups (P < 0.001). Nonetheless, the HSD group continued to demonstrate slightly higher Ptr than the NSD group (P < 0.05). Urinary LTE(4) excretion significantly increased in the HSD group compared with the NSD group within treatment groups. This study has demonstrated that dietary salt loading exacerbated the development of HIAO in guinea pigs and that LT release was involved in HIAO and may be moderated by changes in dietary salt loading.
Subject(s)
Airway Obstruction/physiopathology , Hyperventilation/physiopathology , Physical Exertion/physiology , Sodium Chloride, Dietary/pharmacology , Animals , Body Weight , Bronchoconstriction/drug effects , Bronchoconstriction/physiology , Eating , Electrolytes/urine , Guinea Pigs , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/urine , Lipoxygenase Inhibitors/pharmacology , Male , Masoprocol/pharmacology , Sodium Chloride/pharmacologyABSTRACT
Stem cell factor (SCF) is directly involved in the induction of airway hyperreactivity during allergen-induced pulmonary responses in mouse models. In these studies, we examined the specific mediators and mechanisms by which SCF can directly induce airway hyperreactivity via mast cell activation. Initial in vitro studies with bone marrow-derived mast cells indicated that SCF was able to induce the production of bronchospastic leukotrienes, LTC(4) and LTE(4). Subsequently, when SCF was instilled in the airways of naive mice, we were able to observe a similar induction of LTC(4) and LTE(4) in the bronchoalveolar lavage (BAL) fluid and lungs of treated mice. These in vivo studies clearly suggested that the previously observed SCF-induced airway hyperreactivity may be related to the leukotriene production after SCF stimulation. To further investigate whether the released leukotrienes were the mediators of the SCF-induced airway hyperreactivity, an inhibitor of 5-lipoxygenase (5-LO) binding to the 5-LO activating protein (FLAP) was utilized. The FLAP inhibitor MK-886, given to the animals before intratracheal SCF administration, significantly inhibited the release of LTC(4) and LTE(4) into the BAL fluid. More importantly, use of the FLAP inhibitor nearly abrogated the SCF-induced airway hyperreactivity. In addition, blocking the LTD(4)/E(4), but not LTB(4), receptor attenuated the SCF-induced airway hyperreactivity. In addition, the FLAP inhibitor reduced other mast-derived mediators, including histamine and tumor necrosis factor. Altogether, these studies indicate that SCF-induced airway hyperreactivity is dependent upon leukotriene-mediated pathways.
Subject(s)
Leukotrienes/biosynthesis , Mast Cells/metabolism , Respiratory Hypersensitivity/metabolism , Stem Cell Factor/metabolism , Animals , Arachidonate 5-Lipoxygenase/metabolism , Benzopyrans/pharmacology , Carboxylic Acids/pharmacology , Cells, Cultured , Female , Histamine/biosynthesis , Indoles/pharmacology , Leukotriene Antagonists/pharmacology , Leukotriene C4/biosynthesis , Leukotriene D4/antagonists & inhibitors , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/biosynthesis , Lipoxygenase Inhibitors/pharmacology , Mast Cells/cytology , Mast Cells/drug effects , Methacholine Chloride/pharmacology , Mice , Propionates/pharmacology , Quinolines/pharmacology , Signal Transduction/drug effects , Stem Cell Factor/pharmacology , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
Furosemide (Fur) may have an anti-inflammatory effect on airways in patients with asthma although its intrinsic mechanism remains elusive. Platelet-activating factor (PAF) is a potent proinflammatory mediator that induces systemic and respiratory effects in normal control subjects and asthmatics. The aim of this study was to assess whether pretreatment with nebulized Fur (40 mg) was able to modulate PAF-induced systemic and respiratory effects in asthma. Eleven patients were studied (mean+/-sem 22+/-0.8 yrs) with mild asthma (forced expiratory volume in one second, 95+/-4%) in a randomized, double-blind, placebo-controlled, cross-over fashion, one week apart. PAF challenge (18 microg) was carried out 15 min after administration of Fur or placebo. Peripheral blood neutrophils, respiratory system resistance, and arterial blood gases were measured at baseline, and 5, 15 and 45 min after PAF; urinary cysteinyl leukotriene E4 (uLTE4) was also measured, at baseline and 120 min after PAF challenge. Although Fur did not alter PAF-induced systemic and respiratory effects, it did partially inhibit (63%; p<0.04) the increments of uLTE4 levels shown after PAF inhalation. It is concluded that furosemide is not effective in protecting against platelet-activating factor challenge in patients with asthma despite its potential inhibition of leukotriene synthesis. These findings reinforce the view that the pulmonary effects of platelet-activating factor are mediated through different pathways.
Subject(s)
Asthma/physiopathology , Bronchoconstriction/drug effects , Furosemide/pharmacology , Platelet Activating Factor/antagonists & inhibitors , Pulmonary Gas Exchange/drug effects , Administration, Inhalation , Adult , Airway Resistance , Asthma/drug therapy , Asthma/metabolism , Blood Gas Analysis , Creatinine/urine , Cross-Over Studies , Double-Blind Method , Female , Forced Expiratory Volume , Furosemide/administration & dosage , Humans , Leukocyte Count , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/biosynthesis , Leukotriene E4/urine , Male , Nebulizers and Vaporizers , Platelet Activating Factor/pharmacologyABSTRACT
The two geminal ethyl groups in the succinic acid moiety of CGP57698 (4-[3-(7-fluoro-2-quinolinyl-methoxy)phenyl-amino]-2,2-diethyl-4-oxo- butanoic acid) are responsible for the high in vitro and in vivo potency of this peptidoleukotriene antagonist of the quinoline type. The synthesis and structure activity relationships of CGP57698 and its analogs are described.
Subject(s)
Leukotriene Antagonists/chemical synthesis , Leukotriene D4/antagonists & inhibitors , Quinolines/chemistry , Quinolines/chemical synthesis , Animals , Anti-Asthmatic Agents/chemical synthesis , Anti-Asthmatic Agents/chemistry , Anti-Asthmatic Agents/pharmacology , Biological Availability , Bronchoconstriction/drug effects , Callithrix , Guinea Pigs , Indicators and Reagents , Leukotriene Antagonists/chemistry , Leukotriene Antagonists/pharmacology , Leukotriene E4/antagonists & inhibitors , Molecular Conformation , Molecular Structure , Quinolines/pharmacology , Rats , Structure-Activity RelationshipABSTRACT
Our primary goal has been to discover leukotriene biosynthesis inhibitors with characteristics that are appropriate for use as clinical agents. The success of the use of zileuton in the treatment of asthma led us to explore further the use of the N-hydroxyurea class of 5-lipoxygenase inhibitors as longer-acting compounds with good lung penetration. A variety of in vitro and in vivo methods were used to evaluate a large number of compounds, from which ABT-761 [(R)-N-(3-(5-(4-fluorophenylmethyl)thien-2-yl)-1-methyl-2-pr opynyl)-N-hydroxyurea] was selected for study. ABT-761 exhibited potent and selective inhibition of leukotriene formation both in vitro and in vivo. More importantly, the compound potently inhibited antigen-induced bronchospasm in guinea pigs when given either prophylactically or therapeutically. In addition, ABT-761 was a potent inhibitor of eosinophil influx into the lungs of Brown Norway rats. These data provide added support for the role of leukotrienes in both bronchospasm and eosinophilic inflammation and characterize ABT-761 as a particularly potent inhibitor of leukotrienes formed in pulmonary tissues. These data combined with the excellent pharmacokinetic characteristics of the compound indicate its potential use in the treatment of leukotriene-dependent human disease.
Subject(s)
Bronchoconstriction/drug effects , Enzyme Inhibitors/pharmacology , Hydroxyurea/analogs & derivatives , Lipoxygenase Inhibitors , Pneumonia/drug therapy , Animals , Enzyme Inhibitors/therapeutic use , Eosinophils/pathology , Guinea Pigs , Humans , Hydroxyurea/pharmacology , Hydroxyurea/therapeutic use , In Vitro Techniques , Leukotriene E4/antagonists & inhibitors , Macaca fascicularis , Male , Mice , Muscle Contraction/drug effects , Pneumonia/pathology , RatsABSTRACT
The influence of endotoxin on the hepatic metabolism and elimination of 3H-leukotriene C4 (LTC4) and 3H-leukotriene E4 was studied in the single-pass perfused rat liver. Endotoxin (4 mg/kg body mass) was injected intraperitoneally 8 to 10 hours before livers were isolated for perfusion. Tritiated leukotriene C4 and leukotriene E4 (10 nmol/L) were infused for 5 minutes, and metabolites in bile were determined by high-pressure liquid chromatography. In livers without endotoxin pretreatment, single-pass uptake of LTC4 was 77.3% +/- 3.2%, and 73.8% +/- 1.8% of the radioactivity taken up was excreted into the bile within 80 minutes. In endotoxin-pretreated livers, LTC4 uptake was 62.8% +/- 3.5% and only 31.2% +/- 1.5% of the radioactivity taken up was eliminated into the bile within 80 minutes. Bile flow was reduced to 0.20 +/- 0.07 microL/min, compared with 1.18 +/- 0.18 microL/g/min in untreated livers. Biliary excretion of infused 3H-LTE4 was also reduced in endotoxin-pretreated livers (31.5% +/- 6.1% compared with 61.4% +/- 3.3% without endotoxin pretreatment), whereas uptake was not significantly different. The effect of cellular hydration state on leukotriene processing was also investigated. Anisoosmotic cell volume changes did not influence uptake and biliary excretion of 3H-LTC4 and its metabolism in control livers. In endotoxin-pretreated livers, however, cell swelling induced by hypotonic perfusion media (225 mOsm/L) or by 3 mmol/L glutamine increased biliary elimination of the radioactivity taken up by 68% and 54%, respectively. Bile flow was also stimulated (0.31 +/- 0.09 microL/g/min and 0.46 +/- 0.01 microL/g/min, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Endotoxins/pharmacology , Leukotriene C4/metabolism , Leukotriene D4/metabolism , Leukotriene E4/metabolism , Liver/metabolism , Animals , Bile/metabolism , Colchicine/pharmacology , Leukotriene E4/antagonists & inhibitors , Liver/cytology , Male , Perfusion , Rats , Rats, Wistar , Water/metabolismABSTRACT
OBJECTIVE: Both thromboxane A2 and peptide leukotrienes D4/E4 have been implicated in the pathophysiology of circulatory shock. In the present study, we evaluated the effect of thromboxane A2 and leukotriene D4/E4 receptor antagonism in circulatory shock. DESIGN: Prospective, randomized, controlled trial. SETTING: Research laboratory. SUBJECTS: Male Sprague-Dawley rats (325 to 375 g). INTERVENTIONS: The effect of selective receptor antagonists of thromboxane A2 (i.e., SQ-29,548) and leukotrienes D4/E4 (i.e., LY-171883) was investigated, either alone or in combination, in a model of hemorrhagic circulatory shock. Animals were randomly assigned to one of eight experimental groups: a) sham plus vehicle; b) sham plus LY-171883 (4 mg/kg); c) sham plus SQ-29,548 (2 mg/kg); d) sham plus SQ-29,548 (2 mg/kg) plus LY-171883 (4 mg/kg); e) hemorrhage plus vehicle; f) hemorrhage plus LY-171883 (4 mg/kg); g) hemorrhage plus SQ-29,548 (2 mg/kg); and h) hemorrhage plus SQ-29,548 (2 mg/kg) plus LY-171883 (4 mg/kg). Circulatory shock was induced by acute hemorrhage to a mean arterial pressure (MAP) of 45 mm Hg. We investigated the effect of SQ-29,548 and LY-171883 on the progression of circulatory shock. MEASUREMENTS AND MAIN RESULTS: Neither pharmacologic agent, alone or in combination, had any significant effect on MAP or heart rate in nonhemorrhaged rats. Both thromboxane receptor antagonism (p < .01) and combined thromboxane/leukotriene receptor antagonism (p < .001) significantly improved survival time after hemorrhage. However, leukotriene receptor antagonism alone did not significantly improve survival time after hemorrhage. After acute blood loss and 20% decompensation, the shed blood was returned to the animal; maximal postreinfusion blood pressures were not significantly different between experimental groups. The postreinfusion MAP was maintained at higher values in hemorrhaged rats given the thromboxane receptor antagonist or the combination of thromboxane and leukotriene receptor antagonists. Only the combined therapy significantly altered all of the measured indices of cardiovascular compensation (i.e., maximum bleed-out volume, time to maximum blood loss, and 20% decompensation time). Furthermore, only combined receptor antagonism resulted in a significant (p < .02) attenuation of plasma cathepsin D activity. CONCLUSIONS: The present findings support a role for thromboxane A2 and peptide leukotrienes D4/E4 as important mediators in circulatory shock and suggest that combined thromboxane/leukotriene receptor antagonism may have superior therapeutic efficacy to leukotriene receptor antagonism.
Subject(s)
Acetophenones/administration & dosage , Hydrazines/administration & dosage , Leukotriene Antagonists , Receptors, Thromboxane/antagonists & inhibitors , Shock, Hemorrhagic/drug therapy , Tetrazoles/administration & dosage , Animals , Blood Pressure/drug effects , Blood Volume , Bridged Bicyclo Compounds, Heterocyclic , Cathepsin D/blood , Fatty Acids, Unsaturated , Leukotriene D4/antagonists & inhibitors , Leukotriene D4/physiology , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/physiology , Male , Prospective Studies , Random Allocation , Rats , Rats, Sprague-Dawley , Shock, Hemorrhagic/blood , Shock, Hemorrhagic/physiopathology , Thromboxane A2/antagonists & inhibitors , Thromboxane A2/physiologySubject(s)
Asthma/drug therapy , Leukotriene Antagonists , Airway Obstruction/drug therapy , Airway Obstruction/physiopathology , Asthma/physiopathology , Bronchoconstriction/drug effects , Humans , Leukotriene B4/antagonists & inhibitors , Leukotriene B4/physiology , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/physiology , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/physiology , Leukotrienes/physiologyABSTRACT
The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methyli ndol- 3-yl]methyl]-3-methoxy-N-[(2-methyl-phenyl)sulfonyl]benzamide (38p, ZENECA ZD3523), which has been chosen for clinical evaluation. This compound exhibited a Ki of 0.42 nM for displacement of [3H]LTD4 on guinea pig lung membranes, a pKB of 10.13 +/- 0.14 versus LTE4 on guinea pig trachea, and an oral ED50 of 1.14 mumol/kg opposite LTD4-induced bronchoconstriction in guinea pigs. The R enantiomer was found to be modestly more potent than the S enantiomer 38o. Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity. Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist. The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazoli dinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in > 99% enantiomeric purity.
Subject(s)
Indoles/chemical synthesis , Leukotriene D4/antagonists & inhibitors , Leukotriene E4/antagonists & inhibitors , Animals , Bronchoconstriction/drug effects , Cell Membrane/drug effects , Cell Membrane/metabolism , Guinea Pigs , Indoles/chemistry , Indoles/pharmacology , Leukotriene D4/metabolism , Leukotriene D4/pharmacology , Leukotriene E4/metabolism , Lung/drug effects , Lung/metabolism , Molecular Structure , Stereoisomerism , Structure-Activity Relationship , Trachea/drug effects , Trachea/metabolismABSTRACT
Guinea pig inferior vena cava contracted in response to leukotriene (LT)C4, LTD4, LTE4 U46619, phenylephrine, histamine, and KCl. Although LTC4, LTD4, and U46619 were the most potent agonists, active tension generated by these eicosanoids was only about half that of histamine or KCl. LTE4 and phenylephrine were marginally active. Biochemical analysis showed vena cava able to convert about 23% LTC4 to LTD4 and LTE4 in 45 min. Pretreatment with acivicin prevented this by abrogating conversion of LTC4 to LTD4. A subthreshold concentration of LTE4 reduced responses to LTC4 and LTD4. LY171883 and WY-48252 competitively antagonized LTD4-induced contractions of vena cava. In contrast, these antagonists blocked contractions to LTC4 in a biphasic manner. Lower segments of the LTC4 concentration-response curves were less affected than the upper portion suggesting the possibility of 2 LTC4 receptor subtypes. Our results indicate that LTE4 is a weak or partial agonist in this tissue and furthermore they suggest a lack of high affinity receptors for LTE4 favoring LTC4 and LTD4. Indomethacin did not influence contractions to the leukotrienes or histamine. However, the response to U46619 was greatly enhanced suggesting release of a vasodilator prostaglandin as part of the overall response of the vena cava to the thromboxane A2 mimetic.